Dandu Biosciences
Dandu Biosciences Private Limited is a dynamic biotechnology company specializing in the advancement of biosimilars and complex generic products. Founded in October 2022, the company has made rapid progress in developing innovative biopharmaceuticals, including a cutting-edge peptide platform that reduces production costs. Their key products include Liraglutide, Insulin Glargine, and Semaglutide, with ongoing optimization and development. The company's vision is to become a global leader in biosimilars, providing high-quality, accessible, and affordable pharmaceutical solutions to address unmet medical needs worldwide.
Industries
Nr. of Employees
medium (51-250)
Products
GLP-1 receptor agonist peptide therapeutic (development candidate)
A GLP-1 class peptide therapeutic being developed for glycemic control and weight management; intended for injectable auto-injector and combination formulations.
Insulin analogs and short-acting insulin formulations
Development of long- and short-acting insulin analog formulations intended for vials and cartridge-filled auto-injector pens.
Recombinant peptides and therapeutic proteins
Recombinant peptides and proteins under development for therapeutic and non-therapeutic applications, including serum proteins and wound-healing factors.
Enzymes for industrial and therapeutic workflows
Portfolio of industrial and therapeutic enzymes produced in microbial systems and supplied in high-activity, stabilized formats for food processing and biomanufacturing.
Growth factors and wound-healing proteins
Development and supply of growth factors that support epithelial and tissue repair for wound-healing applications.
Protein-based nutraceutical ingredients
Protein ingredients formulated to supply key amino acids, support gut microbiome balance and provide immunomodulatory activity for nutritional products.
GLP-1 receptor agonist peptide therapeutic (development candidate)
A GLP-1 class peptide therapeutic being developed for glycemic control and weight management; intended for injectable auto-injector and combination formulations.
Insulin analogs and short-acting insulin formulations
Development of long- and short-acting insulin analog formulations intended for vials and cartridge-filled auto-injector pens.
Recombinant peptides and therapeutic proteins
Recombinant peptides and proteins under development for therapeutic and non-therapeutic applications, including serum proteins and wound-healing factors.
Enzymes for industrial and therapeutic workflows
Portfolio of industrial and therapeutic enzymes produced in microbial systems and supplied in high-activity, stabilized formats for food processing and biomanufacturing.
Growth factors and wound-healing proteins
Development and supply of growth factors that support epithelial and tissue repair for wound-healing applications.
Protein-based nutraceutical ingredients
Protein ingredients formulated to supply key amino acids, support gut microbiome balance and provide immunomodulatory activity for nutritional products.
Services
R&D development services for biologics and peptides
Discovery and pre-clinical development services for peptide therapeutics, recombinant proteins and growth factors, including formulation and early-stage characterization.
Pilot cGMP manufacturing (DS & DP)
Pilot-scale cGMP manufacturing of drug substance and drug product, with microbial bioreactors and cGMP DS/DP delivery capability.
Enzyme supply (R&D and cGMP grade)
Supply and formulation of research-grade and cGMP-grade enzymes produced in yeast and bacterial expression systems, delivered as high-concentration or liquid formulations.
Nutraceutical ingredient development
Development of protein-based nutraceutical ingredients and natural sweetener formulations focused on nutritional needs and product stability.
R&D development services for biologics and peptides
Discovery and pre-clinical development services for peptide therapeutics, recombinant proteins and growth factors, including formulation and early-stage characterization.
Pilot cGMP manufacturing (DS & DP)
Pilot-scale cGMP manufacturing of drug substance and drug product, with microbial bioreactors and cGMP DS/DP delivery capability.
Enzyme supply (R&D and cGMP grade)
Supply and formulation of research-grade and cGMP-grade enzymes produced in yeast and bacterial expression systems, delivered as high-concentration or liquid formulations.
Nutraceutical ingredient development
Development of protein-based nutraceutical ingredients and natural sweetener formulations focused on nutritional needs and product stability.
Expertise Areas
- Biosimilar development
- Peptide therapeutic development
- Recombinant protein production
- Enzyme manufacturing and formulation
Key Technologies
- High-yield peptide production platform
- Microbial fermentation (including Pichia pastoris)
- Mammalian cell culture
- cGMP drug substance and drug product manufacturing